Pinnacle Associates’s Sarepta Therapeutics SRPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-58,289
| Closed | -$997K | – | 881 |
|
|
2025
Q2 | $997K | Sell |
58,289
-22,589
| -28% | -$964K | 0.01% | 506 |
|
|
2025
Q1 | $5.16M | Sell |
80,878
-3,167
| -4% | -$333K | 0.08% | 234 |
|
|
2024
Q4 | $10.2M | Sell |
84,045
-7,906
| -9% | -$969K | 0.14% | 155 |
|
|
2024
Q3 | $8.87M | Buy |
91,951
+41,836
| +83% | +$5.78M | 0.15% | 162 |
|
|
2024
Q2 | $7.92M | Sell |
50,115
-40,203
| -45% | -$5.16M | 0.12% | 184 |
|
|
2024
Q1 | $11.7M | Sell |
90,318
-1,633
| -2% | -$200K | 0.18% | 140 |
|
|
2023
Q4 | $8.87M | Sell |
91,951
-212
| -0.2% | -$20.3K | 0.15% | 165 |
|
|
2023
Q3 | $11.2M | Sell |
92,163
-3,236
| -3% | -$366K | 0.21% | 126 |
|
|
2023
Q2 | $10.9M | Sell |
95,399
-2,146
| -2% | -$277K | 0.19% | 136 |
|
|
2023
Q1 | $13.4M | Sell |
97,545
-1,879
| -2% | -$244K | 0.28% | 109 |
|
|
2022
Q4 | $12.9M | Sell |
99,424
-2,190
| -2% | -$254K | 0.28% | 103 |
|
|
2022
Q3 | $11.2M | Sell |
101,614
-6,547
| -6% | -$660K | 0.26% | 119 |
|
|
2022
Q2 | $8.11M | Sell |
108,161
-347
| -0.3% | -$25.5K | 0.18% | 145 |
|
|
2022
Q1 | $8.48M | Sell |
108,508
-2,080
| -2% | -$159K | 0.15% | 164 |
|
|
2021
Q4 | $9.96M | Buy |
110,588
+562
| +0.5% | +$48K | 0.17% | 147 |
|
|
2021
Q3 | $10.2M | Sell |
110,026
-3,960
| -3% | -$305K | 0.19% | 138 |
|
|
2021
Q2 | $8.86M | Buy |
113,986
+3,490
| +3% | +$265K | 0.16% | 155 |
|
|
2021
Q1 | $8.23M | Buy |
110,496
+39,116
| +55% | +$3.61M | 0.16% | 149 |
|
|
2020
Q4 | $12.2M | Sell |
71,380
-4,886
| -6% | -$724K | 0.25% | 111 |
|
|
2020
Q3 | $10.7M | Sell |
76,266
-3,400
| -4% | -$517K | 0.25% | 108 |
|
|
2020
Q2 | $12.8M | Sell |
79,666
-1,570
| -2% | -$214K | 0.32% | 92 |
|
|
2020
Q1 | $7.95M | Sell |
81,236
-13,535
| -14% | -$1.55M | 0.24% | 115 |
|
|
2019
Q4 | $12.2M | Sell |
94,771
-9,005
| -9% | -$909K | 0.27% | 105 |
|
|
2019
Q3 | $7.82M | Sell |
103,776
-4,865
| -4% | -$575K | 0.18% | 145 |
|
|
2019
Q2 | $16.5M | Sell |
108,641
-86,766
| -44% | -$10.5M | 0.39% | 67 |
|
|
2019
Q1 | $23.3M | Sell |
195,407
-5,705
| -3% | -$733K | 0.53% | 51 |
|
|
2018
Q4 | $21.9M | Sell |
201,112
-9,669
| -5% | -$1.21M | 0.57% | 50 |
|
|
2018
Q3 | $34M | Sell |
210,781
-35,285
| -14% | -$4.82M | 0.71% | 35 |
|
|
2018
Q2 | $32.5M | Sell |
246,066
-44,055
| -15% | -$4.15M | 0.67% | 42 |
|
|
2018
Q1 | $21.5M | Sell |
290,121
-12,885
| -4% | -$859K | 0.42% | 66 |
|
|
2017
Q4 | $16.9M | Sell |
303,006
-28,635
| -9% | -$1.52M | 0.32% | 84 |
|
|
2017
Q3 | $15M | Sell |
331,641
-10,175
| -3% | -$407K | 0.28% | 94 |
|
|
2017
Q2 | $11.5M | Sell |
341,816
-19,885
| -5% | -$647K | 0.22% | 115 |
|
|
2017
Q1 | $10.7M | Buy |
+361,701
| New | +$11.2M | 0.2% | 123 |
|
Other funds holding SRPT
EAM
Pinnacle Associates's SRPT Position: Q3 2025 in Review
Pinnacle Associates sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 58,289 shares — an estimated $997K sold.
Pinnacle Associates first reported a position in SRPT in Q1 2017 and held it in 34 quarters. The position peaked at $34M in Q3 2018. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.
- Pinnacle Associates reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
- Pinnacle Associates sold 58,289 Sarepta Therapeutics shares in Q3 2025, an estimated $997K.
- Pinnacle Associates first reported a position in Sarepta Therapeutics in Q1 2017 and held it in 34 quarters.
- Pinnacle Associates's Sarepta Therapeutics position peaked at $34M in Q3 2018.
- 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.
Based on Pinnacle Associates's 13F filing for Q3 2025, filed 13 Nov 2025.